Tyra reports first Phase 2 SURF302 data for dabogratinib in bladder cancer
Tyra Biosciences posted initial ablative-study results in low-grade NMIBC and said a $400 million offering extends its cash runway through 2030.
SEC filing
4 stories
Tyra Biosciences posted initial ablative-study results in low-grade NMIBC and said a $400 million offering extends its cash runway through 2030.
SEC filing
The company priced 9,079,000 shares plus pre-funded warrants at $22.03, expecting to close September 15, 2026 and net about $373.9 million for its FGFR3 programs.
SEC filing (2)
SURF302 trial data show high response rates and manageable safety at 60 mg once-daily, with a registrational study planned for 2027.
SEC filing
Charlton, a pediatric endocrinologist with rare disease drug development experience, joined effective September 1, 2026 as Polaryx prepares to start its SOTERIA trial in the fourth quarter.
SEC filing